like Glucagon-like peptide-1 (GLP-1), is an agonist for the GLP-1 receptor. The clinical utility of native Exendin-4 is limited by its short half-life in plasma. Developed with ConjuChem's proprietary PC-DAC(TM) technology, PC-DAC(TM):Exendin-4 is a modified Exendin-4 analog that is being developed for Type II diabetes. The Exendin-4 analog is covalently bound to recombinant human albumin (Recombumin(R), provided by Novozymes Biopharma). Data from Phase I/II clinical studies have demonstrated that the preformed albumin-peptide conjugate has a much longer half-life and efficacy than the peptide alone. The product is a highly soluble liquid formulation that is injectable in a small volume (less than or equal to 0.2ml) with a 31 gauge needle and is stable in pre-filled syringes at room temperature for a minimum of one month.
Recombumin is the world's first and only animal-free, commercially available recombinant human albumin approved for use in the manufacture of human therapeutics. Recombumin(R) offers the advantages of human serum albumin in a GMP, regulatory friendly package.
ConjuChem, developer of next generation medicines from therapeutic peptides, is creating long-acting compounds based on bioconjugation platform technologies. When applied to peptides, the Company's systemic PC-DAC(TM) Technologies enable the creation of new drugs with significantly enhanced therapeutic properties as compared to the original peptide.
Detailed descriptions of the Company and its technologies can be viewed on the Company's website www.conjuchem.com.
About Novozymes and Novozymes Biopharma
Novozymes is the world leader in bio-innovations. Together with customers across a broad array of industries, the Company creates tomorrow's industrial bio-solutions, which
Page: 1 2 3 Related biology technology :1
|SOURCE ConjuChem Biotechnologies Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. ConjuChem Provides Development Update2
. Novozymes Launches Enzyme to Reduce Acrylamide in Food3
. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.4
. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems5
. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training6
. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers7
. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.18
. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees9
. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products10
. Neogen Acquires Kane Enterprises11
. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma